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Objective: Describe and assess the impact of a
pharmacist-led patient review programme on the
management and control of type 2 diabetes (T2D).
Design: Uncontrolled prospective cohort study with
before and after intervention data collection.
Setting: General practices within NHS Slough Clinical
Commissioning Group (CCG).
Participants: 5910 patients with T2D.
Interventions: Pharmacists reviewed 5910 patients
and worked with general practice teams to schedule
any of the 9 key care processes recommended by the
National Institute for Health and Care Excellence (NICE)
that the patients were lacking, to optimise medication
and to make other interventions such as providing
lifestyle advice.
Main outcome measures: The proportion of
patients receiving the NICE-recommended 9 key care
processes and proportion of patients whose glycated
haemoglobin (HbA1c), blood pressure (BP) or total
cholesterol (TC) readings were over target before and
after the intervention period.
Results: The proportion of patients receiving all of the
NICE-recommended 9 key care processes increased
from 46% at project outset in April 2013 to 58% on
completion in April 2014 and the percentage of
patients achieving HbA1c, BP and TC targets all
increased (65% to 70%, 70% to 76%, 78% to 82%,
respectively). Quality Outcomes Framework (QOF) data
for Slough CCG showed the percentage of diabetic
patients achieving target HbA1c, BP and TC readings
increased from April 2013 to April 2014, but then
diminished in the year after project completion.
Conclusions: The pharmacist-led review increased the
number of key care processes administered and
improved diabetic control during the year of programme
delivery. The improvement abated during the year after,
suggesting that such programmes should be ongoing
rather than fixed term. The programme combined the
strategic drive and project facilitation skills of Slough
CCG, the general practice teams’ knowledge of their
patients and the clinical and information technology
skills of an experienced pharmacist team.
INTRODUCTION
People in England can receive healthcare
provided free at the point of delivery by the
government-funded National Health Service
(NHS). Patients register with a general prac-
titioner (GP) practice which comprises of at
least one GP and a wider team of healthcare
professionals and administrative staff. Every
GP practice (Practice) in England is a
member of 1 of more than 200 Clinical
Commissioning Groups (CCGs). CCGs are
clinically led statutory bodies responsible
Strengths and limitations of this study
▪ An example of effective multidisciplinary team
working, this project was able to deliver
improved focus on type 2 diabetes (T2D) man-
agement in NHS Slough Clinical Commissioning
Group (CCG) by combining the strategic drive
and project facilitation skills of the CCG, the
general practice teams’ drive to deliver ever
higher standards of service to their patients and
the clinical and information technology system
expertise of an experienced pharmacist team.
▪ This project represents a good example of the
aspirations of the joint working initiatives created
by the Royal College of General Physicians and
the Royal Pharmaceutical Society in order to
identify areas where general practitioners and
pharmacists can work together to improve the
quality of patient care.
▪ The key limitation when evaluating the outcomes
of this project is that it represented just one
element of the overall package of care received
by the patients. However, within the outcomes
reported, the increase in the number of patients
receiving all nine of the NICE-recommended nine
key care processes (from 48% to 58% of
patients) can be more clearly attributed to the
project, as the lists of missing care processes
per each patient were generated by the pharma-
cists and then systematically worked through by
the general practice teams.
▪ While a clinical programme such as this carries
associated financial costs, it is widely accepted
that the financial costs of managing poorly con-
trolled T2D patients (and the associated compli-
cations) far exceed the costs of managing
well-controlled T2D patients.
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for the planning and commissioning of healthcare ser-
vices that meet the needs of the local population. Their
success is measured by how much they improve health
outcomes.
Type 2 diabetes (T2D) is a complex condition to
manage. When T2D is not well managed, it is associated
with considerable morbidity and serious complications,
including heart disease, stroke, diabetic retinopathy,
kidney disease and amputation—over time leading to
disability and premature mortality.1 In addition to the
clinical burden of T2D care, there are also substantial
ﬁnancial costs associated with it.1 Since 1996, the
number of people diagnosed with diabetes in the UK
has increased from 1.4 million to 2.9 million, and by
2025, it is estimated that there will be 5 million people
with diabetes in the UK.2 To add to the growing burden
of diabetes, an estimated 850 000 people in the UK are
currently living with undiagnosed T2D and in diag-
nosed patients, by the time of diagnosis, ∼50% of T2D
patients show signs of complications.2 Around £10
billion (or 10%) of the NHS budget is spent on dia-
betes. The total cost (direct care and indirect costs)
associated with diabetes in the UK currently stands at
£23.7 billion and is predicted to rise to £39.8 billion by
2035/2036.2
The prevalence of (diagnosed) T2D in NHS Slough
CCG is higher than the national average and is increas-
ing. According to the National Diabetes Audit 2012/
2013, which was published during the project year, only
a minority (40.0%) of T2D patients in NHS Slough CCG
achieved all treatment targets recommended by the
National Institute for Health and Clinical Excellence
(NICE).3 This was consistent with the national picture.
With too few patients achieving all treatment targets, the
need for improvement was key to delivering better
patient care.
The nine key care process that NICE recommends
that each patient with diabetes should receive each year
are:
1. Glycated haemoglobin (HbA1c) measurement, with a
suggested target of 59 mmol/mol.
2. Blood pressure (BP) measurement, with a suggested
target of 140/80 mm Hg.
3. Cholesterol level measurement, with a suggested
target for total cholesterol (TC) of 5 mmol/L.
4. Retinal screening.
5. Foot checks.
6. Urinary albumin testing.
7. Serum creatinine testing.
8. Weight check.
9. Smoking status check.
Given the local picture regarding the quality of T2D
management and the future projections of a substantial
increase in T2D prevalence, NHS Slough CCG identiﬁed
the improved management of T2D as a key strategic pri-
ority.4 Recently published studies demonstrate that
pharmacist support can improve the safety of prescrib-
ing, improve the quality of care for long-term conditions
and reduce readmissions rates.5–9 Within the UK, there
is currently a policy drive to use clinical pharmacists
more effectively in primary care.6
Based on this and with a need to deliver improve-
ments in patient outcomes, NHS Slough CCG commis-
sioned the services of an experienced clinical
pharmacist team. Each pharmacist would become part
of the general practice team at each site for the duration
of the programme. Much of the published data on
pharmacist intervention to improve the care for people
with T2D are based on pharmacists working in
Community Pharmacies or clinics rather than being inte-
grated into general practice teams.10
METHODS
Led by a senior pharmacist and a team of three clinical
pharmacists, the clinical programme was delivered
between April 2013 and April 2014. To ensure a high
level of continuity within the work delivered, each of the
13 GP practices participating in the programme was
assigned to 1 of the 3 clinical pharmacists, who worked
with the same GP practices throughout the year. The
programme consisted of three phases.
The ﬁrst phase of the project involved data collection,
analysis and work-stream prioritisation. The aim of this
phase was to benchmark current achievements within
T2D (and comorbidities) management, to engage with
general practice teams and to allow the pharmacists to
prioritise patient cohorts for review in line with relevant
NICE and local guidance. Software was created to
execute identical information searches on the clinical
systems at each Practice at each phase of the project.
Each practice gave permission for anonymised summary
statistics from each phase of the project to be reported
back to NHS Slough CCG. No patient-identiﬁable data
were removed from each Practice. Key activities at phase
I of the project included:
▸ Identiﬁcation of patients who were missing any of the
NICE-recommended nine key care processes,
▸ Referral of patients to receive any missing or outdated
care processes,
▸ Identiﬁcation of patients for further review where
HbA1c, BP and TC targets not achieved,
▸ Educational sessions for practice personnel in opti-
mising T2D management and control.
Following the analysis of practice performance in rela-
tion to the NICE-recommended nine key care processes
in the ﬁnancial year prior to project initiation in April
2013, the ﬁndings were discussed with key personnel
within each GP practice. A tailored strategy to increase
the percentage of patients receiving all of the
NICE-recommended nine key care processes was
designed and agreed with each Practice.
The second phase of the programme was designed to
optimise treatment for those patients identiﬁed in phase
I as having failed to achieve their HbA1c, BP and TC
targets. The data from phase I combined with a detailed
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clinical review of each poorly controlled patient enabled
the pharmacists to make recommendations to enhance
treatment where appropriate. Recommendations for
each individual patient were discussed at a multidiscip-
linary team meeting including the GP who was the
project lead at each Practice, who then decided the
most appropriate course of action to take with each
patient. Recommendations made included but were not
limited to drug initiations, dose changes, drug disconti-
nuations, interventions regarding adherence to and per-
sistence with treatment, lifestyle and diet advice, and
referring to specialist care where complications were
identiﬁed.
Each practice decided how different recommenda-
tions should be actioned. In some instances, the GP
opted to action recommendations opportunistically
when patients attended. However, recommendations
were usually actioned proactively using a mix of clinic
consultations, telephone consultations and letters to
patients. Delivery of the agreed interventions was gener-
ally shared out between the general practice team and
the pharmacist.
During phase III of the programme, each Practice
received a follow-up visit from the pharmacist at 6 and
12 months post-phase II in order to evaluate the impact
of interventions made during phases I and II. The aim
of these visits was to assess the extent to which agreed
recommendations had been implemented, to
implement any outstanding actions, to identify further
opportunities for improvement through reaudit and to
maintain practice engagement in the project.
RESULTS
During phase I, the pharmacist team identiﬁed 3211
patients missing at least 1 of the NICE-recommended 9
key care processes. A plan was agreed with each practice
to ensure that the missing care processes were com-
pleted with each patient wherever possible.
Figure 1 shows that the proportion of patients receiv-
ing all of the NICE-recommended nine key care pro-
cesses was increased from 46% at the beginning of the
project to 58% at the end of the project, and that the
proportion of patients receiving less than seven of the
nine key care processes reduced from 21% to 15%.
Figure 2 shows that in April 2013 at the project outset,
the percentage of patients completing seven of the nine
care processes (weight, BP, smoking status, HbA1c,
serum creatinine, TC and foot examination) was below
the England and Wales average. Only the percentage of
patients with urinary albumin assessment was above the
England and Wales average. Comparative data relating
to eye examinations were not available. In April 2014,
after the clinical programme was completed, the per-
centage of patients who had received eight of the nine
care processes had improved in comparison to the
Figure 1 NICE-recommended nine key care processes: achievement before and after project delivery.
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previous year. In all except for the assessment of weight,
there was an increase in the proportion of patients
recorded as receiving each individual care process from
project start to project completion (ﬁgure 2).
During phase I of the project, a total of 2984 of the
5910 patients were found by the pharmacist team to be
at risk of poor T2D control as deﬁned by their latest
HbA1c, BP or TC readings being over the NICE recom-
mended target. However, some readings were over
1-year-old, and where this was the case, the pharmacists
worked with the Practices to try to arrange new tests.
This was often achieved but at times not until late into
the project, meaning that there were fewer actions or
recommendations that the pharmacist could make for
such patients within the project timeframe. Such
patients had to be ﬂagged for more detailed review by
the Practice team on completion of out-of-date care
processes.
The pharmacists were able to undertake a more
detailed review of the notes of each patient whose latest
overtarget HbA1c, BP or TC readings were less than a
year old. Recommendations were made to the GP as to
how treatment could be optimised for each such patient.
In addition to arranging for these patients to have any
missing care processes put in place as previously
described, there were 1035 patients for whom opportun-
ities to optimise medication were recommended to the
GP.
Table 1 shows the number and proportion of patients
whose latest HbA1c, BP or TC readings were overtarget
at the start versus the end of the project. It can be seen
that by the end of the project, a greater proportion of
the population had an HbA1c, BP and/or TC reading in
their record, and a lower percentage of the readings
were overtarget.
The way that the project was designed meant that only
those patients with an overtarget HbA1c, BP or TC
reading taken within 12 months of project initiation
were able to receive the most detailed review from the
pharmacist team. Table 2 shows the number of patients
with an overtarget HbA1c, BP or TC reading taken
within 12 months of project initiation, who then had a
further reading taken after they had been extensively
reviewed by the pharmacist in collaboration with the GP
at each practice.
Table 3 contains data relating to the percentage of all
diabetic patients across NHS Slough CCG whose HbA1c,
BP and TC were overtarget in the ﬁnancial year ending
prior to project delivery starting (April 2013), at the
ﬁnancial year end which coincided with the completion
of project delivery (April 2014) and at the ﬁnancial year
end 1 year after project delivery had completed (April
2015). These data were reported by practices via the
Quality Outcomes Framework (QOF) reporting
process.11
Table 3 shows that the percentage of patients whose
HbA1c, BP and TC readings were overtarget were at
their lowest levels on completion of the project before
increasing again in the year after project delivery had
completed.
Figure 2 Achievement of the NICE-recommended nine key care processes before and after project delivery and against the
2012/2013 average for England and Wales:3 weight, blood pressure, smoking status, glycated haemoglobin, urinary albumin,
serum creatinine, total cholesterol, eye check and foot check.
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LIMITATIONS AND DISCUSSION
This pharmacist-led review programme of patients with
T2D showed an increase in the percentage of patients
who had all of the nine NICE-recommended nine key
care processes completed and a decrease in the number
of patients considered to be poorly controlled. This adds
to the evidence for improvements in outcomes in T2D
when pharmacists are involved.8 10
The ﬁndings of this study are distinguishable from
much of the data previously published because the phar-
macists involved were integrated into already existing
general practice teams, which is the model currently
being proposed by the Royal College of General
Physicians and the Royal Pharmaceutical Society.5 The
pharmacists were acting as clinicians, making patient-
speciﬁc recommendations. They also used information
technology (IT) skills to interrogate electronic medical
records to identify the individuals with T2DM who were
at greatest risk of complications and target the work of
different members of the general practice team. This
meant that resource was appropriately attributed to each
patient based on need and based on the skills of each
member of the team. Such an approach would be widely
replicable because it does not require signiﬁcant
changes to patient pathways or the development of new
providers but simply the inclusion of a new staff member
with a different skill set into an already existing team.
The key limitation when evaluating the outcomes of
this project is that it represented just one element of the
overall package of care received by the patients between
April 2013 and April 2014. It is therefore not possible to
say exactly how many of the patients whose HbA1c, BP
or TC levels came back into target range were as a direct
result of the problem identiﬁcation and the interven-
tions delivered within this project, and how many would
have come back into range if the project had not taken
place. Potential confounding factors that were not con-
trolled for include: local clinicians receiving training on
the management of T2D from other sources, the mar-
keting and subsequent prescribing of new treatments for
T2D or improvements or changes to other commis-
sioned services for T2D locally.
What is known is that a proportion of those patients
who were well controlled at the project outset, or who
appeared after the project outset, failed to achieve at
least one of the HbA1c, BP or TC targets during the
year of project delivery, because while tables 1 and 3
show a reduction in the proportion of poorly controlled
patients across the CCG as a whole during the project
delivery year, the reductions are not on the scale of
Table 2 Number of patients with up to date, overtarget glycated haemoglobin, blood pressure or total cholesterol readings at
project outset, whose readings were repeated after project phase I
Care process
Overtarget reading taken within the
year preceding project initiation
Overtarget when reading
repeated after pharmacist review Change
HbA1c >59 mmol/mol 940 659 −29.9%
BP >140/80 mm Hg 639 454 −29.0%
TC >5 mmol/L 595 324 −45.5%
Table 1 Number and percentage of patients with glycated haemoglobin, blood pressure or total cholesterol readings at
project start and end
Phase I—project start—T2D population of 5910.
April 2013
























HbA1c 5467 92.50% 1937 35% 5932 96.71% 1765 30%
BP 5617 95.04% 1680 30% 6043 98.52% 1455 24%
TC 5127 86.75% 1125 22% 5820 94.88% 1019 18%




Financial year end April
2013 (project started)
Financial year end April
2014 (project completed)
Financial year end April 2015
(1 year postproject completion)
HbA1c >59 mmol/mol 34.18% 27.41% 31.21%
BP >140/80 mm Hg 22.98% 15.03% 15.34%
TC >5 mmol/L 20.14% 16.80% 18.87%
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those observed in the most extensively reviewed cohort
of patients which were tracked in table 2.
Table 2 shows that where patients underwent a
detailed review by the pharmacist in collaboration with
the Practice team, 29–45.5% of their markers of poor
control at project outset improved to the point of achiev-
ing target by the end of the project, yet table 1 shows
that the overall numbers of patients whose latest reading
were still overtarget at the end of the project had not
reduced by the same proportions. There were three
main reasons for this:
▸ Because of the progressive nature of T2D when
poorly managed, many patients whose T2D was well
controlled at the project outset had become poorly
controlled during the year of project delivery.
▸ Some patients had outdated readings at the project
outset which indicated good T2D control but which
were updated during the course of project delivery
and on occasion revealed that control had
diminished.
▸ The T2D population under review increased from
5910 to 6134 during the project year, bringing with it
a proportion of patients with overtarget readings.
An analysis of QOF data (a national database, inde-
pendent of this study) relating to time periods before,
during and after project delivery was undertaken and is
shown in table 3. Within the overall NHS Slough CCG
population, the proportion of patients above the recom-
mended targets for HbA1c, BP and TC were lower for
all three parameters at the point of project completion
than they had been in the QOF year preceding project
delivery. The likelihood that this improvement was at
least partially attributable to the project was perhaps
further reinforced by the fact that the percentage of
patients exceeding each of the three parameters once
again increased in the year following project comple-
tion. This also suggests that a rolling programme would
be more beneﬁcial than a ﬁxed term project, and
emphasises the importance of building a strong educa-
tional legacy with the Practices so that they can continue
to deliver a similar programme.
The increase in the percentage of patients receiving
all nine of the NICE-recommended nine key care pro-
cesses (from 48% to 58% of patients) can be more
clearly attributed to the project, as the lists of missing
care processes per each patient were generated by the
pharmacists and then systematically worked through by
the practices.
However difﬁcult it is to isolate the impact of this
‘real life’ clinical programme, it did succeed in identify-
ing and focusing attention and resource on the poorly
controlled T2D patients within NHS Slough CCG
between April 2013 and April 2014. Missing care pro-
cesses were completed for those patients, who were also
recommended for priority review by their practices with
a host of treatment optimisation recommendations sug-
gested by the pharmacists. Going forward, NHS Slough
CCG is targeting further improvements in T2D control,
and the learning and outcomes from this programme
give conﬁdence that improved outcomes could be
achieved again, but that more consideration should be
given as to how practices might be able to routinely
incorporate more of the patient identiﬁcation, monitor-
ing and tracking into their day-to-day activities in order
to derive more of a legacy effect if the service cannot
be provided every year.
As an example of effective multidisciplinary team
working, this programme was able to deliver improved
focus on T2D management in NHS Slough CCG by
combining the strategic drive and project facilitation
skills of the CCG, the practices’ drive to deliver ever
higher standards of service to their patients and the
clinical and IT system expertise of an experienced
pharmacist team. It represents a good example of the
aspirations of the joint working initiatives created by
the Royal College of General Physicians and the Royal
Pharmaceutical Society to identify areas where GPs and
pharmacists can work together to improve patient
care.5
While a clinical programme such as this carries asso-
ciated ﬁnancial costs, it is widely accepted that the ﬁnan-
cial costs of managing poorly controlled T2D patients
(and the associated complications) far exceed the costs
of managing well-controlled T2D patients.1 Therefore, a
relatively modest investment in a clinical programme
such as this may help to ensure that the NICE-recom-
mended key care processes are completed, monitored
and acted on in order to reduce morbidity, mortality and
healthcare costs, while also improving Practice and CCG
performance against the QOF.11
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